INSMED Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
INSM$116.10+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. Exhibits
Exhibit Index
| 3.1 | Articles of Incorporation of Insmed Incorporated, as amended through June 14, 2012 (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Annual Report on Form 10-K filed on March 18, 2013). |
| 3.2 | Amended and Restated Bylaws of Insmed Incorporated (effective as of May 11, 2023) (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Current Report on Form 8-K filed on May 11, 2023). |
| 10.1** | Amendment No. 1 to Insmed Incorporated Amended and Restated 2019 Incentive Plan (incorporated by reference from Appendix A to Insmed Incorporated’s Proxy Statement on Schedule 14A, filed on April 1, 2024). |
| 10.1.1** | Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. |
| 10.1.2** | Form of Award Agreement for Non-Qualified Stock Options to non-U.S. employees pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. |
| 10.1.3** | Form of Award Agreement for Restricted Stock Units pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. |
| 10.1.4** | Form of Award Agreement for Restricted Stock Units to non-U.S. employees pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. |
| 10.2** | Omnibus Amendment to Insmed Incorporated Incentive Awards and Inducement Awards, dated May 8, 2024. |
| 10.3** | Form of Non-Qualified Stock Option Inducement Award Agreement. |
| 10.4** | Form of Non-Qualified Stock Option Inducement Award Agreement for non-U.S. employees. |
| 10.5* | Commercialization Agreement, dated July 8, 2014, between Insmed Incorporated and PARI Pharma GmbH. |
| 10.5.1* | Amendment No. 1 to the Commercialization Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017. |
| 31.1 | Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
| 31.2 | Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
| 32.1 | Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. |
| 32.2 | Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. |
| 101 | The following materials from Insmed Incorporated’s quarterly report on Form 10-Q for the quarter ended June 30, 2024 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023, (ii) Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023, (iii) Consolidated Statements of Shareholders' Deficit for the three and six months ended June 30, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023, (v) Notes to the Unaudited Consolidated Financial Statements, and (vi) Cover Page. |
| 104 | The cover page from the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in iXBRL and contained in Exhibit 101. |
- Certain portions of this exhibit have been redacted.
** Management contract or compensatory plan or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.